Similar articles

• Perforating dermatosis in a patient receiving bevacizumab.

  Vano-Galvan S, Moreno C, Medina J, Pérez-García B, García-López JL, Jaén P. Vano-Galvan S, et al. J Eur Acad Dermatol Venereol. 2009 Aug;23(8):972-4. doi: 10.1111/j.1468-3083.2008.03078.x. Epub 2009 Mar 17. J Eur Acad Dermatol Venereol. 2009. PMID: 19470057 No abstract available.
• Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.

  Duffy A, Shia J, Huitzil-Melendez FD, Fong Y, O'Reilly EM. Duffy A, et al. Clin Colorectal Cancer. 2008 Mar;7(2):140-3. doi: 10.3816/CCC.2008.n.019. Clin Colorectal Cancer. 2008. PMID: 18501074
• The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.

  Malik Z, Eng C. Malik Z, et al. Clin Adv Hematol Oncol. 2007 Jan;5(1 Suppl 1):4-7. Clin Adv Hematol Oncol. 2007. PMID: 17491584 No abstract available.
• [Advances in the treatment of metastatic colorectal cancer with bevacizumab].

  Longo F, Mansueto G. Longo F, et al. Tumori. 2006 Sep-Oct;92(5):suppl 1-12. Tumori. 2006. PMID: 17168449 Review. Italian. No abstract available.
• Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.

  Heinemann V, Hoff PM. Heinemann V, et al. Oncology. 2010;79(1-2):118-28. doi: 10.1159/000314993. Epub 2010 Nov 22. Oncology. 2010. PMID: 21088438 Review.